Will Another Alzheimer’s Disease Drug Bite the Dust After Lilly’s Latest Results?
There's a pressing need for safe and effective treatments for Alzheimer's disease. However, there haven't been many successes after ...
Tag: Lillys
What to look for in Lilly’s eagerly awaited Alzheimer’s data
Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease, Eli Lilly issued a ...
Biogen & Lilly’s amyloid-targeting drugs race for FDA approval
With Eli Lilly’s donanemab and Biogen’s aducanumab jockeying for position in the race for key regulatory approvals, the so-called ...
Eli Lilly’s Stock Has Swung on Alzheimer’s Drug Developments. What Investors Need to Know.
Text size Eli Lilly’s headquarter in Indianapolis Jonathan Weiss/Dreamstime When Eli Lilly presented the results of a small study ...
Europe’s vaccine safety scare & Eli Lilly’s Alzheimer’s data
Has Europe lost the plot with Covid-19 vaccines? Can the latest treatment for Alzheimer’s disease succeed where so many ...
Vaccine vexed; plus assessing Lilly’s Alzheimer’s data & PDUFA preview: a BioCentury podcast
BioCentury & Getty ImagesProduct Development By Jeff Cranmer, Executive Editor Mar 16, 2021 | 1:28 AM GMTThe solely factor ...
Lilly’s donanemab slowed Alzheimer’s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM | Antibodies
Lilly's donanemab slowed Alzheimer's illness development in Section 2 trial: full knowledge introduced at AD/PD™ 2021 and printed in ...
